Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma
Academic Article
Overview
MeSH Major
Continuity of Patient Care
Patient Care Bundles
Patient Discharge
abstract
Seventy-one percent of patients with advanced soft-tissue sarcomas had positive scintigraphy scans demonstrating tumor expression of somatostatin receptors subtype 2 in vivo. Imaging with indium-111 pentetreotide could be studied as an adjunct to conventional imaging modalities for assessment of sarcoma patients. Further research is needed to determine the prognostic implications of somatostatin receptor subtype 2 positivity, including larger studies to evaluate any potential correlation with metastatic behavior and other clinical outcomes.
